On November 14, 2022 Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, reported its financial and operational results for the three and nine months ended September 30, 2022 (Press release, Nuvo Pharmaceuticals, NOV 14, 2022, View Source [SID1234624012]). For further details on the results, please refer to Miravo’s Management, Discussion and Analysis (MD&A) and Condensed Consolidated Interim Financial Statements for the three and nine months ended September 30, 2022, which are available on the Company’s website (www.miravohealthcare.com). All figures are in Canadian dollars, unless otherwise noted.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The work on winding down our manufacturing operations continues and based on the final order book for Pennsaid and Pennsaid 2% production, we now anticipate completing all manufacturing and quality release testing activities during the second half of 2023."

Tweet this
Key Developments

Three months ended September 30, 2022 include the following:

Total revenue was $18.1 million, an increase of 7% compared to $17.0 million for the three months ended September 30, 2021. Adjusted total revenue(1) was $18.2 million, an increase of 6% compared to $17.1 million for the three months ended September 30, 2021.
Net income was $0.4 million compared to a net loss of $17.8 million for the three months ended September 30, 2021. Adjusted EBITDA(1) was $5.7 million, a decrease of 19% compared to $7.0 million for the three months ended September 30, 2021.
Revenue related to the Blexten franchise, Cambia and Suvexx was $10.7 million, an increase of 32% compared to revenue of $8.1 million for the three months ended September 30, 2021. Total Canadian prescriptions of Blexten, Cambia and Suvexx increased by 27%, 7% and 86%, respectively compared to the three months ended September 30, 2021.
The Company repaid $3.2 million (US$2.5 million) of the Amortization Loan to Deerfield Management Company, L.P. (Deerfield).
As at September 30, 2022, cash and cash equivalents were $31.3 million.
Nine months ended September 30, 2022 include the following:

Total revenue was $54.7 million, an increase of 7% compared to $51.2 million for the nine months ended September 30, 2021. Adjusted total revenue(1) was $57.3 million, an increase of 11% compared to $51.6 million for the nine months ended September 30, 2021.
Net income was $20.8 million compared to a net loss of $26.6 million for the nine months ended September 30, 2021. Adjusted EBITDA(1) was $19.1 million, an increase of 2% compared to $18.8 million for the nine months ended September 30, 2021.
Revenue related to the Blexten franchise, Cambia and Suvexx was $31.6 million, an increase of 34% compared to revenue of $23.5 million for the nine months ended September 30, 2021. Total Canadian prescriptions of Blexten, Cambia and Suvexx increased by 21%, 5% and 94%, respectively compared to the nine months ended September 30, 2021.
The Company repaid $9.9 million (US$7.8 million) of the Amortization Loan to Deerfield.
(1)
Non-IFRS financial measure. These measures are not recognized under IFRS and do not have standardized meanings prescribed by IFRS. See the Non-IFRS Measures section for definitions, reconciliations and the basis of presentation of the Company’s non-IFRS measures.

Business Update

In August 2022, Miravo announced the appointment of Anthony Snow to its Board of Directors. Mr. Snow has over twenty years of experience investing in and advising public and private companies. Mr. Snow is currently the President and Co-Portfolio Manager of Red Oak Partners, LLC. He also serves as President and a director of CBA Florida, Inc. (previously known as Cord Blood America, Inc.). Prior to joining Red Oak Partners, Mr. Snow worked at Soros Fund Management where he was part of a two-person team that managed a global long/short equity portfolio. Prior to Soros, he also focused on global equities at both Ardea Capital Management, as part of the founding team, and Wyper Capital Management. Previously, Mr. Snow was an Associate at private equity firm Lindsay Goldberg. Mr. Snow began his career at Merrill Lynch & Co. as an Analyst in the Mergers & Acquisitions group. Mr. Snow received a B.B.A. with high distinction from the University of Michigan, concentrating in finance and accounting, and an M.B.A. from Harvard Business School.
In August 2022, Miravo’s U.S. partner for Pennsaid 2% announced it would be winding down the business segment that currently promotes and sells Pennsaid 2% in the U.S. in response to the market erosion resulting from an at-risk launch of a generic version of Pennsaid 2% in May 2022. The Company has conducted a thorough evaluation of its manufacturing operations based in Varennes, Québec, where it manufactures Pennsaid 2%, and has determined that its continued operation of its manufacturing facility is no longer viable as a result of this lost revenue stream. Miravo is exploring strategic alternatives to monetize its manufacturing facility and related intellectual property, while winding down its manufacturing operations. The Company anticipates that a wind-down of its manufacturing operations will conclude during the second half of 2023, depending on various factors, some of which are beyond the Company’s control.
"Our Canadian commercial business segment continues to deliver consistent year-over-year sales growth driven primarily by prescription growth of our key promoted brands of Blexten, Cambia and Suvexx. In our international Licensing and Royalty segment, we remain on track for a 2023 launch of Suvexx in select EU markets through our partner Orion," said Jesse Ledger, Miravo’s President & CEO.

Mr. Ledger went on to state, "The work on winding down our manufacturing operations continues and based on the final order book for Pennsaid and Pennsaid 2% production, we now anticipate completing all manufacturing and quality release testing activities during the second half of 2023."

Third Quarter 2022 Financial Results

Adjusted total revenue was $18.2 million and $57.3 million for the three and nine months ended September 30, 2022 compared to $17.1 million and $51.6 million for the three and nine months ended September 30, 2021. The $1.1 million increase in adjusted total revenue in the current quarter was primarily attributable to a $2.6 million increase in revenue from the Commercial Business segment, offset by a $1.5 million decrease in revenue from the Licensing and Royalty Business segment and $0.1 million in amounts billed to customers for existing contract assets.

Revenue attributable to the Commercial Business segment increased during the three months ended September 30, 2022 due to a $2.5 million increase in sales of the Company’s promoted products (Blexten, Cambia, Suvexx and NeoVisc) and a $0.1 million increase in sales of the Company’s mature products. Revenue attributable to the Licensing and Royalty Business segment decreased during the three months ended September 30, 2022 due to a $1.0 million reduction in ex-U.S. Vimovo royalties due to the expiry of the royalty term for certain territories and a $0.3 million reduction in Yosprala royalties, as the Company’s entitlement to royalties on Takeda’s net sales of Cabpirin ended with the patent expiry on May 31, 2022 and a $0.2 million reduction in the U.S. Vimovo royalty.

The $5.7 million increase in adjusted total revenue in the nine months ended September 30, 2022 was primarily attributable to a $7.7 million increase in revenue from the Commercial Business segment and a $2.2 million increase in amounts billed to customers for existing contract assets, offset by a $1.8 million decrease in revenue from the Licensing and Royalty Business segment and a $2.4 million decrease in revenue from the Production and Service Business segment. Revenue attributable to the Commercial Business segment increased during the nine months ended September 30, 2022 due to a $8.0 million increase in sales of the Company’s promoted products (Blexten, Cambia, Suvexx and NeoVisc), offset by a $0.3 million decrease in revenue for the Company’s mature products.

The $1.8 million decline in license revenue during the current nine-month period was primarily attributable to a $1.0 million reduction in ex-U.S. Vimovo royalties due to the expiry of the royalty term for certain territories, a $0.8 million reduction in the U.S. Vimovo royalty due to a step-down in royalty to 5% of net sales compared to 10% of net sales for a portion of the comparative nine-month period and a $0.3 million reduction in Yosprala royalties, as the Company’s entitlement to royalties on Takeda’s net sales of Cabpirin ended with the patent expiry on May 31, 2022. In the nine months ended September 30, 2022, the Company received $2.3 million (US $1.8 million) for Yosprala-related milestone revenue billed to its Japanese licensee for its then existing contract asset. The $2.4 million decrease in product sales from the Production and Service Business segment during the current nine-month period was primarily attributable to a decrease in Pennsaid 2% and Pennsaid sales.

Adjusted EBITDA was $5.7 million for the three months ended September 30, 2022 compared to $7.0 million for the comparative quarter. During the three months ended September 30, 2022, a $1.6 million increase in gross profit from the Commercial Business segment was more than offset by a $1.5 million decrease in the gross profit contribution from the Company’s Licensing and Royalty Business segment, a $0.5 million decrease in the gross profit contribution from the Company’s Production and Service Business segment, a $0.4 million increase in sales and marketing expenses, a $0.4 million increase in G&A expenses and a $0.1 million decrease in amounts billed to customers for existing contract assets.

Adjusted EBITDA was $19.1 million for the nine months ended September 30, 2022 compared to $18.8 million for the nine months ended September 30, 2021. During the nine months ended September 30, 2022, a $4.7 million increase in gross profit from the Commercial Business segment and a $2.2 million increase in amounts billed to customers for existing contract assets was more than offset by a $2.3 million decrease in gross profit contribution from the Production and Service Business segment, a $1.8 million decrease in the contribution from the License and Royalty Business segment, a $1.0 million increase in sales and marketing expenses and a $1.4 million increase in G&A expenses net of a $0.2 reduction in stock-based compensation expenses.

Non-IFRS Measures

The Company discloses non-IFRS financial measures (adjusted total revenue, adjusted EBITDA, and cash value of loans) and non-IFRS ratios (adjusted EBITDA per share and net debt leverage ratio) that are not recognized under and do not have standardized meanings prescribed by IFRS. Accordingly, such measures are not necessarily comparable and may not have been calculated in the same way as similarly named financial measures presented by other companies. These measures should be considered as supplemental in nature and not as a substitute for related financial information prepared in accordance with IFRS. The Company believes that shareholders, investment analysts and other readers find such measures and ratios helpful in understanding and assessing the Company’s financial performance. We utilize these measures in managing our business, including as means of performance measurement, cash management, debt compliance and assessing leverage and borrowing capacity. Because non-IFRS financial measures and non-IFRS ratios do not have standardized meanings prescribed under IFRS, securities regulations require that such measures be clearly defined, identified, and for non-IFRS financial measures, reconciled to their nearest IFRS measure. The applicable definition, calculation and reconciliation of each such measure used in this press release is provided below.

Adjusted Total Revenue

The Company defines adjusted total revenue as total revenue, plus amounts billed to customers for existing contract assets, less revenue recognized upon recognition of a contract asset. Management believes adjusted total revenue is a useful supplemental measure to determine the Company’s ability to generate cash from its customer contracts used to fund its operations.

Adjusted EBITDA

EBITDA refers to net income (loss) determined in accordance with IFRS, before depreciation and amortization, net interest expense (income) and income tax expense (recovery). The Company defines adjusted EBITDA as EBITDA, plus amounts billed to customers for existing contract assets, inventory step-up expenses, stock-based compensation expense, loss on fair value of derivative liabilities, loss on fair value of contingent and variable consideration, impairment loss, foreign currency loss, other losses less revenue recognized upon recognition of a contract asset, stock-based compensation recovery, gain on fair value of derivative liabilities, gain on fair value of contingent and variable consideration, impairment recovery, foreign currency gain and other income. Management believes adjusted EBITDA is a useful supplemental measure to determine the Company’s ability to generate cash available for working capital, capital expenditures, debt repayments, interest expense and income taxes.

(1)Income tax expense for the three and nine months ended September 30, 2022, includes $0.5 million and $2.5 million for deferred income tax due to the utilization of loss carry forwards that were previously recognized [$0.7 million and $2.1 million for the three and nine months ended September 30, 2021].

(2)In the three and nine months ended September 30, 2022, the impairment loss of $0.9 million included a $46 write-down of certain mature intangible assets and $0.3 million for Resultz goodwill in the Commercial Business segment and a $0.6 million write-down of certain intangible assets in the Licensing and Royalty Business segment [$14.7 million of impairment losses on goodwill and certain intangible assets in the Commercial Business and Licensing and Royalty segments for the three and nine months ended September 30, 2021].

(3)The Company’s derivative liabilities are measured at fair value through profit or loss at each reporting date. As a result of the decrease in the share price in the current quarter and a decrease in the volatility of the Company’s shares, amongst other inputs, the value of the Company’s derivative liabilities decreased and the Company recognized net non-cash gains of $3.5 million on the change in fair value of derivative liabilities for the three months ended September 30, 2022 [$2.9 million net non-cash losses for the three months ended September 30, 2021]. During the nine months ended September 30, 2022, as a result of the decrease in the share price and a decrease in the volatility of the Company’s shares, amongst other inputs, the value of the Company’s derivative liabilities decreased and the Company recognized net non-cash gains of $26.1 million on the change in fair value of derivative liabilities [$14.4 million net non-cash losses for the nine months ended September 30, 2021].

Management to Host Conference Call/Webcast

Management will host a conference call to discuss the results today (Monday, November 14, 2022) at 11:00 a.m. ET. To participate in the conference call, please dial (416) 764-8646 or 1 (888) 396-8049 / Conference ID: 80555289. Please call in 15 minutes prior to the call to secure a line. You will be put on hold until the conference call begins.